Evidence map›Paper›PMID 42113893›Full record

ArticlePLoS biology2026

USP39 promotes antiviral defense through post-transcriptional control of RIG-I and stabilization of STING.

Jiazheng Quan, Xibao Zhao, Shaoying Chen, Hongrui Li, Wei Chen, Qianqian Di, Xunwei Li, Jiajing Zhao, Han Wu, Jin Chen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jiazheng QuanGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Xibao ZhaoGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Shaoying ChenGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Hongrui LiInstitute of Immunology, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.
Wei ChenGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Qianqian DiGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Xunwei LiGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Jiajing ZhaoGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Han WuGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Jin ChenGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Yue XiaoGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Zherui WuGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
Weilin ChenGuangdong Provincial Key Laboratory of Infection Immunity and Inflammation, Marshall Laboratory of Biomedical Engineering, Institute of Biological Therapy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.ORCID https://orcid.org/0000-0002-0335-4483

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RIG-I and STING are critical for mediating the RIG-I and cGAS-STING signaling pathways that guard against viral infection. Here, we report that ubiquitin-specific peptidase 39 (USP39) positively regulates the RIG-I and cGAS-STING pathways to induce antiviral innate immunity in vitro and in vivo. The USP39 deficiency impaired the antiviral immune response of macrophages, leading to low type I IFNs expression, and high RNA and (e.g., VSV, H1N1 PR8) DNA virus (e.g., HSV-1) replication. Moreover, USP39-deficient mice were more sensitive to VSV or HSV-1 infection than control mice. Conversely, USP39 overexpression promoted the antiviral immune response. Mechanistically, we found that USP39 regulates RIG-I protein expression by promoting pre-RIG-I mRNA splicing and maturation. In addition, we also revealed that USP39 interacts with and stabilizes STING protein by deubiquitinating K48-linked polyubiquitin of STING at K288. These data show that USP39 positively regulates RNA and DNA-virus-induced RIG-I and cGAS-STING signaling, respectively, by promoting post-transcriptional control of RIG-I and stabilization of STING. These data provide new insights and potential therapeutic targets to control viral infections.

Indexed as

DEAD Box Protein 58Membrane ProteinsUbiquitin-Specific ProteasesAnimalscGAS-STING Signaling PathwayCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseHumansImmunity, InnateInterferon Type IMacrophagesMiceMice, Inbred C57BLMice, KnockoutNucleotidyltransferasesSignal TransductionSTING ProteincGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseDdx58 protein, mouseDEAD Box Protein 58Interferon Type IMembrane ProteinsNucleotidyltransferasesSting1 protein, mouseSTING ProteinUbiquitin-Specific Proteases

Identifiers

PMID42113893
PMCPMC13178990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.